secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001213900-25-066995
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics gets Nasdaq transfer to Capital Market and 180-day bid-price extension
--------------------------------------------------------------------------------

- Nasdaq approved transfer to Capital Market effective July 24, 2025.
- Company granted until January 19, 2026 to regain $1 minimum bid price compliance.
- Must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.
- Company intends to monitor bid price and take reasonable measures to maintain listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/0001213900-25-066995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025066995/ea0249919-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-066995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer